Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Celgene will sell the psoriasis treatment Otezla to Amgen for $13.4 billion in cash. The sale is intended to win US Federal Trade Commission clearance for Bristol-Myers Squibb’s $74 billion acquisition of Celgene, which was announced in January. After that deal was revealed, the FTC indicated that the combination of Otezla with a similar BMS drug in the late stages of development would be anticompetitive. The Otezla sale is contingent on the FTC’s approval of the Celgene-BMS deal.
This article has been sent to the following recipient: